Hussman Strategic Advisors Inc. Buys Shares of 6,300 Alnylam Pharmaceuticals, Inc. $ALNY

Hussman Strategic Advisors Inc. bought a new stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 6,300 shares of the biopharmaceutical company’s stock, valued at approximately $2,505,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Root Financial Partners LLC bought a new position in Alnylam Pharmaceuticals during the 3rd quarter valued at about $25,000. Salomon & Ludwin LLC bought a new position in Alnylam Pharmaceuticals during the 3rd quarter valued at about $27,000. Caitong International Asset Management Co. Ltd bought a new position in Alnylam Pharmaceuticals during the 3rd quarter valued at about $29,000. Ameriflex Group Inc. bought a new position in Alnylam Pharmaceuticals during the 3rd quarter valued at about $32,000. Finally, ORG Partners LLC lifted its stake in Alnylam Pharmaceuticals by 70.2% during the 3rd quarter. ORG Partners LLC now owns 80 shares of the biopharmaceutical company’s stock valued at $36,000 after acquiring an additional 33 shares during the period. Institutional investors own 92.97% of the company’s stock.

Insider Activity at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, insider Melissa Mclaughlin sold 2,286 shares of the firm’s stock in a transaction that occurred on Monday, April 6th. The shares were sold at an average price of $330.42, for a total transaction of $755,340.12. Following the sale, the insider owned 9,443 shares in the company, valued at approximately $3,120,156.06. This trade represents a 19.49% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, EVP Jeffrey V. Poulton sold 2,206 shares of the firm’s stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $327.65, for a total transaction of $722,795.90. Following the sale, the executive vice president owned 64,273 shares in the company, valued at approximately $21,059,048.45. The trade was a 3.32% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 38,656 shares of company stock worth $12,370,696 in the last 90 days. Insiders own 0.86% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on the stock. Oppenheimer assumed coverage on shares of Alnylam Pharmaceuticals in a research note on Wednesday, January 7th. They set an “outperform” rating and a $500.00 target price on the stock. Morgan Stanley lowered their target price on shares of Alnylam Pharmaceuticals from $495.00 to $408.00 and set an “equal weight” rating on the stock in a research note on Friday, January 30th. Barclays initiated coverage on shares of Alnylam Pharmaceuticals in a research note on Wednesday, January 28th. They issued an “overweight” rating and a $527.00 price objective on the stock. Jefferies Financial Group reiterated a “hold” rating and issued a $330.00 price objective (down from $522.00) on shares of Alnylam Pharmaceuticals in a research note on Monday, March 16th. Finally, Weiss Ratings cut shares of Alnylam Pharmaceuticals from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Monday, April 6th. One equities research analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $471.96.

More Alnylam Pharmaceuticals News

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: Q1 beat driven by Amvuttra — Alnylam reported Q1 EPS of $1.99 and revenue of $1.17B, topping estimates; Amvuttra sales surged ~187% and helped drive 96% year‑over‑year revenue growth. Read More.
• Positive Sentiment: Brokerage support — Several brokerages continue to rate ALNY favorably (consensus around “moderate buy” and H.C. Wainwright remains a buy), which supports upside sentiment over the medium term. Read More.
• Neutral Sentiment: Mixed analyst target moves — Wells Fargo nudged its target slightly higher but kept an “equal weight” stance; RBC trimmed its target marginally but maintains an “outperform” view (still implying sizeable upside). These are tweaks rather than directional shifts. Read More. Read More.
• Neutral Sentiment: Investor materials and commentary available — Full earnings slide deck and call transcript were published (useful for modeling product-level trends and guidance; contributes to re‑rating discussions). Read More.
• Negative Sentiment: Risks and product headwinds — The quarter showed declines in collaborator revenue and Onpattro sales that offset some gains; an outside review highlighted a new regulatory risk and warned the stock could carry a higher risk of significant losses, which likely pressured sentiment. Read More.

Alnylam Pharmaceuticals Price Performance

Shares of NASDAQ:ALNY opened at $296.11 on Friday. The firm’s 50 day moving average price is $320.11 and its 200-day moving average price is $376.83. Alnylam Pharmaceuticals, Inc. has a twelve month low of $245.96 and a twelve month high of $495.55. The company has a quick ratio of 2.71, a current ratio of 2.76 and a debt-to-equity ratio of 1.28. The stock has a market capitalization of $39.51 billion, a PE ratio of 80.90 and a beta of 0.31.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings data on Thursday, April 30th. The biopharmaceutical company reported $1.99 earnings per share for the quarter, topping the consensus estimate of $0.90 by $1.09. Alnylam Pharmaceuticals had a net margin of 11.72% and a return on equity of 118.63%. The firm had revenue of $1.17 billion for the quarter, compared to analysts’ expectations of $1.12 billion. During the same quarter in the prior year, the business earned ($0.44) EPS. The business’s quarterly revenue was up 96.4% on a year-over-year basis. Equities research analysts expect that Alnylam Pharmaceuticals, Inc. will post 6.78 EPS for the current year.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.